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Breast and prostate cancers are the most common malignant
diseases among women and men, respectively in Europe and the
USA (Harris et al, 1997). Surgical resection or radiation therapy
are potentially curative for localized diseases. Advanced breast
and prostate cancers are associated with a poor prognosis, and
conventional chemotherapies and radiation therapy are still of
limited effectiveness. Endocrine therapies usually lead to either a
partial or complete remission. However, subsequent relapse often
occurs, and the disease re-emerges within a few years. Innovative
approaches for advanced disease are necessary.
Arsenic is a naturally occurring element; pure arsenic is not
common in the environment. Rather, it is usually found combined
with one or more other elements such as oxygen, chlorine and
sulphur. Arsenic combined with these elements is referred to as
inorganic arsenic, whereas arsenic combined with carbon and
hydrogen is referred to as organic arsenic. Maintaining a distinc-
tion between inorganic and organic arsenic is important, since the
organic forms are usually less toxic. Traditional Chinese medicine
has used an arsenic-containing remedy (Ai-Lin1) for many
different ailments (Mervis, 1996). In the 1940s and 1950s,
Fowler’s solution which contained 1% potassium arsenite was
frequently used for the treatment of chronic myelogenous
leukaemia (Donofrio et al, 1987). Administration of inorganic
arsenic, arsenic trioxide (As2O3), produced a high complete remis-
sion rate, as well as a relatively long-term survival in a significant
proportion of individuals with acute promyelocytic leukaemia
(APL) (Sun et al, 1992; Zhang et al, 1996; Chen et al, 1997;
Soignet et al, 1998). Melarsoprol (Mel-B), an organic arsenical
synthesized by complexing melarsen oxide with dimercaprol, has
primarily been used for the treatment of African trypanosomiasis
(Apted, 1970; Milord et al, 1992; van Nieuwenhove, 1992;
Yunmbam et al, 1993). Mel-B induced apoptosis and inhibited in
vitro growth of B-cell chronic lymphocytic leukaemia cell lines
(König et al, 1997).
Retinoïds are natural and synthetic derivatives of vitamin A
(Bollag et al, 1992). They prevent development as well as growth
of several tumour types in animal models; and clinical trials have
shown efficacy in individuals with APL, leukoplakia and recurrent
squamous tumours of the head and neck (Gudas, 1992).
Furthermore, retinoids inhibit the in vitro growth of a variety of
cancer cells including those from leukaemias, breast, prostate and
pancreas cancers (Douer et al, 1981; Pienta et al, 1993; Teelmann
et al, 1993; Bollag et al, 1994; de Vos et al, 1996; Elstner et al,
1996). The regulation of cell growth and differentiation of normal,
premalignant, and malignant cells by retinoids results from their
effects on gene expression. These effects are mediated by nuclear
retinoid receptors, which are ligand-activated transcription factors
and members of the steroid hormone receptor superfamily (Evans,
1988; Mangelsdorf et al, 1994). Action of retinoids is mediated
either by retinoic acid receptor-a (RAR-a), RAR-b, RAR-g,
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Correspondence to: HP Koefflerand/or by retinoic X receptors (RXR) (Petkovich, 1992). All-trans-
retinoic acid (ATRA) is the first highly effective differentiation-
inducing agent for remission induction in patients with APL
(Huang et al, 1988; Warrell et al, 1993). It is the ligand for RARs.
To our knowledge, this is the first report of the effects of Mel-B
and the combination of Mel-B with ATRA for solid tumours. We
found that Mel-B or the combination of Mel-B and ATRA had
potent anti-tumour activity against human breast and prostate
cancer cells both in vitro and in vivo.
MATERIALS AND METHODS
Mice
Twenty male and twenty female 8-week-old BNX nu/nu mice
were purchased from Harlan Sprague Dawley Inc, (Indianapolis,
IN, USA) and were maintained in pathogen-free conditions with
irradiated chow.
Cell culture
The human DU 145 and PC-3 prostate cancer cell lines and the
MCF-7 breast cancer cell line were obtained from American Type
Culture Collection (Rockville, MD, USA) and were maintained in
RPMI-1640 medium (Gibco Laboratories, Grand Island, NY,
USA) supplemented with 10% fetal calf serum (FCS; Gibco), 100
Um l –1 penicillin and 100 mg ml–1 streptomycin.
Drugs
Melarsoprol {p-[(4,6,-diamino-s-triazin-2-yl)amino]dithiobenzene-
arsonous acid 3-hydroxypropylene ester} was a gift from the
Central Disease Control (Atlanta, GA, USA), prepared in 
180 mg/5 ml ampoules and stored at 4°C. ATRA (Sigma, St Louis,
MO, USA) was dissolved in dimethyl sulphoxide (DMSO) at 10–2
M for in vitro studies and 50 mg ml–1 for in vivo studies. It was
stored at –80°C and protected from light.
Clonogenic assay in soft agar
Potency of drugs to inhibit the clonogenic growth of cancer cells
and the resulting ED50s (effective dose which inhibited 50% of
clonal growth) was determined by extensive dose–response
studies in soft agar. The cells from 60–80% confluent liquid
cultures were plated into 24-well flat bottom plates using a two-
layer, soft-agar system with a total volume of 400 ml, as described
previously (Munker et al, 1986). Drugs were added on day 0 prior
to addition of feeder layer to the culture plates. After 14 days of
cultivation, colonies (> 50 cells) were counted with an inverted
microscope. All experiments were done independently at least
three times in triplicate dishes per experimental point.
Western blot analysis of bcl-2
MCF-7, PC-3 and DU 145 cells were seeded at 1 ´ 105 and
allowed to adhere overnight. The medium was replaced and to it
was added either Mel-B (10–6 M) and/or ATRA (10–7 M). The cells
were incubated with these compounds for 72 h. Lysates were
prepared using Triton X-100 lysis buffer (20 mM Tris. Cl pH 8.0,
137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, and
1m M sodium orthovanadate). One hundred micrograms of the
protein extract was added to each lane of a 10–20% gradient poly-
acrylamide gel. The membrane was blocked in phosphate-buffered
saline (PBS)/5% non-fat milk (MLK) at room temperature and
subsequently incubated with murine monoclonal anti-Bcl-2
(clone100, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 
1 mg ml–1 in PBS/3% MLK for 2 h at room temperature, followed
by incubation with horseradish peroxidase conjugated anti-mouse
Ig (Amersham, Arlington Heights, IL, USA) at 1:1500 in PBS/3%
MLK. An actin monoclonal antibody from Oncogene Research
Products was used as a control protein. The results were visualized
by enhanced chemiluminescence (Amersham), and densitometry
was performed using the Alpha Imager 2000 digital imaging
system with Alpha Ease version 3.0 software (Alpha Innotech
Corp., San Leandro, CA, USA).
Cell cycle analyses
Cell cycle was analysed by flow cytometry. Briefly, cancer cells at
<60% confluency were cultured either with or without analogues
for 3 days in tissue culture medium, trypsinized, washed in DPBS,
fixed in methanol and incubated for 30 min at 4°C in the dark with
a solution of 5 mg ml–1 propidium iodide, 1 mg ml–1 RNAase
(Sigma), and 0.1% Nonidet P-40 (Sigma). Analysis was performed
immediately after staining using the CELLFit program (Becton
Dickinson) whereby the S phase was calculated with a RFit model.
Measurement of apoptosis
After 5 days of cultivation of cancer cells with or without drugs
(Mel-B, 10–6 M; ATRA, 10–7 M), the cells were trypsinized, washed
with DPBS and analysed for apoptosis. Activation of an endo-
nuclease results in extensive DNA cleavage and, thus, generates a
large number of DNA strand breaks in apoptotic cells. DNA frag-
mentation was confirmed in our study by labelling of DNA strand
breaks in apoptotic cells with BrdUTP (Li et al, 1995). This
deoxynucleotide, once incorporated into the DNA strand breaks, is
detected by a fluorescein isothiocyanate (FITC)-conjugated anti-
BrdUrd antibody (Becton Dickinson, San Jose, CA, USA).
Morphologically, cells undergoing apoptosis possess prominent
features such as intense staining, highly condensed and/or frag-
mented nuclear chromatin, a general decrease in overall cell size,
and cellular fragmentation into apoptotic bodies. These features
make apoptotic cells relatively easy to distinguish from necrotic
cells. For morphology, cytospin-slides with cultured cells were
stained by Diff-Quick Stain Set. Apoptotic cells were enumerated
in a total of about 300 cells by light microscopy.
Animal treatment protocol
Several animal studies were performed, using male BNX mice for
the PC-3 prostate cancer experiments and female BNX mice for the
MCF-7 breast cancer cells. Animals were bilaterally, subcuta-
neously injected with 5 ´ 106 of either PC-3 or MCF-7 cells per
tumour in 100 ml Matrigel (Collaborative Biomedical Products,
Bedford, MA, USA). Before injection of cells, the animals received
300 rads whole body irradiation. The mice were divided into four
groups of five mice each, and received either diluant (DMSO) or
experimental agents. Mel-B and ATRA (50 ml per injection) were
administered intraperitoneally thrice weekly. One day after tumour
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or the combination of Mel-B and ATRA. Doses of Mel-B and
ATRA were chosen from our preliminary studies in which various
doses thrice weekly were given and mice were followed for toxi-
city. During the experiments, two mice died: one receiving Mel-B
(10 mg kg–1) and the other in the ATRA group (7.5 mg kg–1) cohort.
The cause of their deaths was unknown. Tumours were measured
every week with vernier calipers. Tumour size was calculated by
the formula: a ´ b ´ c, where a is the length and b is the width and c
is the height in millimetres. At the end of the experiments, blood
was collected from the orbital sinus for serum chemistries and
haematopoietic analyses using Dupont Analyst Benchtop
Chemistry System (Dade International, Newark, DE, USA) and by
Serono-Baker 9000 Diff (Biochem Immuno-Systems, Allentown,
PA, USA) respectively. Animals were sacrificed by carbon dioxide
asphyxiation and tumour weights were measured after their careful
resection.
Histology
Tumours and normal organs from sacrificed mice were fixed in
10% neutral buffered formalin and embedded in paraffin wax prior
to histologic sectioning. Sections were stained with haematoxylin
and eosin, and tumour necrosis and fibrosis were evaluated.
Controls consisted of tumours and organs from mice not subjected
to treatment.
Statistical analysis
All numerical data were expressed as the average of the values
obtained, and standard deviation (s.d.) was calculated. For the in
vitro studies, significance was determined by conducting a paired
Student’s t-test. For the in vivo studies, the statistical significance
of the difference was analysed by the non-parametric Mann–
Whitney  U-test.
RESULTS
In vitro studies
Clonogenic assay
To study the effects of Mel-B, ATRA or their combination on
clonogenic growth of cancer cells, the two-layer soft-agar system
was performed. The MCF-7 breast cancer cells were very sensitive
to the inhibitory effect of Mel-B in clonogenic assay (ED50: 7´ 10–9
M); the prostate cancer cell lines, PC-3 and DU 145 had ED50s of 2
´ 10–7 M, and 3 ´ 10–7 M respectively (Figure 1). The ATRA alone at
10–7 M was only moderately inhibitory of the clonogenic growth of
the PC-3 or DU 145 prostate cancer cells (30% and 27% respec-
tively); however, the same concentration of ATRA (10–7 M) inhib-
ited about 70% clonal growth of the MCF-7 breast cancer cells
(Figure 2). Interestingly, the combination of both drugs (Mel-B,
10–7 M) and ARTA, 10–7 M) had at least an additive effect on clonal
inhibition of each of the cancer cell lines (PC-3: 65% inhibition;
DU 145: 74% inhibition; MCF-7: 90% inhibition) (Figure 2).
Apoptosis and bcl-2 levels
Exposure of the cells to the combination of Mel-B (2 ´ 10–6 M) and
ATRA (10–7 M) for 5 days synergistically induced apoptosis in each
of the cell lines [DU 145 (42%), PC-3 (51%) and MCF-7 cells
(59%)], as measured by DNA fragmentation as compared to
exposure of the cells to either agent alone (Figure 3). A similar,
dramatic effect was observed when assessing apoptosis by
morphology (data not shown).
The effect of Mel-B (10–6 M, 5 days), ATRA (10–7 M, 5 days) or
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Figure 1 Dose–response studies of Mel-B: effect on clonal proliferation of
breast and prostate cancer cells. Results are expressed as a mean per cent
± s.d. of control plates containing no drug. Each point represents a mean of
at least three experiments with each experimental point having triplicate
dishes. The drug was added to the culture dishes on day 0
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Figure 2 Effect of Mel-B and/or ATRA on clonal proliferation of breast and
prostate cancer cells. Results are expressed as a mean percent ± s.d. of
control plates containing no drug. Each point represents a mean of at least
three experiments with each experimental point having triplicate dishes. The
compounds were added to the culture dishes on day 0both on the cellular content of bcl-2 protein was measured by
Western blot (data not shown). When bcl-2 expression was
corrected for actin expression, Mel-B decreased levels by 13%,
ATRA lowered expression by 73%, and both together caused an
86% decrease in bcl-2 levels in the MCF-7 cells. Levels of bcl-2
were lower in the untreated PC-3 and DU 145 cells as compared to
MCF-7, and these levels did not change markedly after exposure to
Mel-B and/or ATRA (data not shown).
In vivo studies
We tested the ability of Mel-B and/or ATRA to inhibit the growth of
MCF-7 breast and PC-3 prostate cancer cells growing in triple
immunodeficient mice. Figure 4 shows the effect of Mel-B and/or
ATRA on the size of PC-3 and MCF-7 tumours during 6 weeks of
therapy. All of the treatment groups had statistically significantly
smaller tumours than the diluant-control groups. Administration of
Mel-B and ATRA alone remarkably suppressed the growth of the
tumours. The size of the PC-3 tumours in mice treated with Mel-B at
5 and 10 mg kg–1 was similar, although the former was slightly
smaller. The most potent effect was observed when Mel-B and
ATRA were administered together to the mice bearing MCF-7
tumours. Besides determining the volume of the tumours over time,
they were carefully dissected at the termination of the study and
weighed. Results paralleled the volume measurements (data not
shown). Tumour weights from each of the treated groups were statis-
tically different from those of the control group, and the combination
of Mel-B and ATRA was more potent than either alone. During the
study, all mice were weighed once per week. The body weights of all
treated groups were 91–101% of that of the control groups (data not
shown). In general, all the mice of each of the cohorts looked healthy.
The blood chemistries (ten different studies including BUN,
creatinine, liver enzymes and electrolytes) and haematopoietic
parameters (including peripheral blood white and red cell counts,
platelet count and white cell differential evaluation) were obtained
at the end of the study. The blood was collected from the orbital
sinus while the animals were anaesthetized. No difference in the
mean values of the blood chemistries were observed between the
treated and untreated animals (data provided on request). The
blood haematopoietic data showed little change between the
cohorts, Group H (Mel-B + ATRA) had slightly higher white
blood cell and platelet counts (data provided on request).
Histology
MCF-7
Tumours from control mice revealed poorly differentiated adeno-
carcinomas with about 30% necrosis and fibrosis (Figure 5A).
Tumours from mice treated with Mel-B showed increased necrosis
and apoptotic bodies (about 60% of the tumour mass) as well as
fibrosis (Figure 5B). Tumours from mice receiving ATRA alone
revealed similar changes in about 40% of each tumour section
(data not shown). Tumours from mice treated with the combina-
tion of ATRA and Mel-B also contained a similar amount of
tumour necrosis and apoptosis (Figure 5C).
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Figure 4 Volume of MCF-7 and PC-3 tumours in BNX mice receiving Mel-B
and ATRA. Human MCF-7 breast or PC-3 prostate cancer cells (5 ´ 106)
were injected subcutaneously, and Mel-B and ATRA were administered
intraperitoneally (M, W, F), for 6 weeks to the BNX nude mice. Tumour
volumes were calculated as the product of the length, width and height (see
Materials and Methods section) of each tumour. Data are expressed as the
mean ± s.d. for eight to ten tumours. Definitions: *, significantly different from
control groups with P < 0.01 and **, significantly (P < 0.01) different between
ATRA (7.5 mg kg–1), and Mel-B and ATRA groups as determined by
Mann–Whitney U-testPC-3
Controls revealed poorly differentiated carcinomas with small foci
of necrosis and fibrosis which constituted approximately 20% of
the area of the tumour section (data not shown). Tumours from
mice treated with Mel-B at 5 or 10 mg kg–1 and/or ATRA 
7.5 mg kg–1 revealed extensive necrosis and fibrosis [50–60% of
each of the tumour sections revealed necrosis and histologic
changes of apoptosis including formation of apoptotic bodies, and
fibrosis involved approximately 30% of the tumour area (data not
shown)].
DISCUSSION
Arsenic compounds have been generally considered to be a poison
and a potent environmental carcinogen for human skin and lung
cancers (Jaafar et al, 1993; Dong et al, 1994). Nevertheless, the
inorganic arsenical, As2O3, induced apoptosis in the NB4 APL cell
line associated with decreased expression of bcl-2 mRNA and
protein (Chen et al, 1996, 1997). Furthermore, clinical studies in
China and the USA have shown that As2O3 is an effective drug for
patients with APL (Sun et al, 1992; Zhang et al, 1996; Chen et al,
1997; Soignet et al, 1998). Laboratory data suggest that the
activity of arsenic in haematopoietic cell lines was independent of
the expression of PML-RARa fusion product which is specific for
the APL cells (König et al, 1997). The organic arsenical, Mel-B, is
used for treatment of trypanosomiasis and this arsenical has been
formulated for human use since 1949 (Friedheim, 1949). Recently,
Mel-B was found to inhibit growth and decrease expression of bcl-
2 in several chronic B-cell leukaemia cell lines (JVM-2, 183CLL,
WSU-CLL) (König et al, 1997). Because arsenicals may have a
broad range of activity, we examined the ability of Mel-B to
inhibit the growth of human breast and prostate cancer cell lines.
Our clonogenic growth assays showed that MCF-7 breast
cancer cells were very sensitive to the inhibitory activity of Mel-B.
Furthermore, the strongest combined effects were observed in the
cells treated with Mel-B and ATRA (Figures 1 and 2). The DU 145
prostate cancer cells are notably resistant to a variety of in vitro
therapies (Thompson, 1994; Israel et al, 1995; deVos et al, 1996;
Campbell et al, 1998); therefore, the sensitivity of these cells to
clonal inhibition of proliferation by Mel-B and their prominent
apoptosis with the combination of Mel-B and ATRA is notable.
The PC-3 prostate cancer cells are moderately resistant to a variety
of agents (Thompson, 1994; Israel et al, 1995; deVos et al, 1996;
Campbell et al, 1998). These cells were also inhibited in their
clonal growth by Mel-B. The Mel-B and ATRA at least additively
decreased clonal growth of these prostate cancer cells.
Comparison of the potency of inorganic As2O3 to Mel-B showed
that Mel-B was about tenfold more potent in its antiproliferative
activities than was As2O3 for each of the breast and prostate cancer
cell lines, suggesting that Mel-B may be more active than As2O3
(data not shown).
The mechanism by which Mel-B mediates its anticancer activity
is unclear. Prior investigation have reported that arsenicals affect
protein tyrosine phosphorylation (Cavigelli et al, 1996; Chen et al,
1998). They can also decrease levels of glutathione which can
result in DNA damage as a result of increased intracellular reac-
tive oxygen molecules (Snow, 1992; Cavigelli et al, 1996).
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Figure 5 Histological findings of MCF-7 breast tumours at the end of
treatment. (A) MCF-7 tumour from control mice demonstrating infiltrating
poorly differentiated adenocarcinoma (see arrow). The malignant cells
appear in sheets with large nuclei, prominent nucleoli, and abundant
cytoplasm. There is no evidence of tumour necrosis. (B) MCF-7 tumour
harvested from mice treated with Mel-B, showing extensive necrosis and
apoptosis (see arrow). There is scant viable tumour remaining at the top of
the field (arrow). The remaining tumour shows only outlines of necrotic cells
with pyknotic nuclei. Dense apoptotic bodies are present (asterisk). (C MCF-7
tumour obtained from mice treated with Mel-B plus ATRA, displaying
extensive necrosis and no viable tumour. Dense aggregates of chromatin
(arrows) are present in a background of acellular tissue necrosisCombination of melarsoprol and retinoid for cancers 457
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Apoptosis or programmed cell death is of importance for the
development and homeostasis of multicellular organisms (Fisher,
1994). Specific therapies have been designed to enhance the
susceptibility of human cancers to undergo apoptosis (Yonish-
Rouach et al, 1991; Symonds et al, 1994). Apoptosis is an active
gene-directed cellular suicide mechanism; and many human genes
contribute to its regulation, such as p53, c-myc and bcl-2 (Shi et al,
1992; Miyashita et al, 1993; Borsellino et al, 1995). We showed
that the combination of Mel-B and ATRA dramatically and signifi-
cantly increased the number of apoptotic cells in each of the three
cancer cell lines, especially MCF-7 breast cancer cells (Figure 4).
This effect was associated with a decrease in levels of bcl-2
protein in the MCF-7 cells (Figure 5). In contrast, levels of bcl-2
protein did not decrease in PC-3 and DU 145 prostate cancer cells
after a similar treatment showing that decrease in existing levels of
bcl-2 are not required for induction of apoptosis of these cells; but
of note, bcl-2 levels were already relatively low in wild-type PC-3
and DU 145 cells. Soignet et al (1998) showed that apoptosis of
APL cells by As2O3 was coincident with activation of caspases
which are cysteine proteases important in mediating programmed
cell death. Of interest after completion of our study, another inves-
tigative group noted that growth of As2O3-resistant NB4 APL cells
was inhibited by the addition of ATRA to the cells (Gianni et al,
1998). Taken together, an arsenical and ATRA can have an
enhanced antitumour effect in vitro; albeit, we do not understand
the mechanism by which this occurs.
Our in vivo studies showed that the Mel-B as well as ATRA
significantly inhibited the growth of PC-3 and MCF-7 cells.
Furthermore, the treatment of MCF-7 breast cancer cells with the
combination of Mel-B and ATRA was statistically superior to either
Mel-B or ATRA alone. These data are consistent with our in vitro
data. Blood chemistries and haematopoietic analyses showed that
WBC and platelet numbers in the combination group were slightly
higher than that of the control group, but all data were within the
normal range (data available on request). Body weights in the exper-
imental animals were within 10% of the control animals.
The histological data showed that all the MCF-7 breast and the
PC-3 prostate tumours were poorly differentiated adenocarci-
nomas. Sections from mice treated with Mel-B and/or ATRA
revealed extensive necrosis, apoptosis and fibrosis involving
approximately 30–60% of the tumour area. Therefore, Mel-B had
anticancer activities in vivo similar to what we observed in vitro.
This activity occurred without major side-effects. The mechanisms
of this anticancer effect remain unclear but are associated with
prominent apoptosis. Toxicity was not discernible raising hopes
that either Mel-B alone or when combined with ATRA may
become a useful adjuvant therapy for breast and prostate cancers.
This may be particularly true for the individuals who have
minimal residual disease after curative attempt by surgery and/or
radiotherapy.
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